BRCA2 and ovarian cancer: With the approval of maintenance therapy with olaparib and bevacizumab for high-grade ovarian cancer patients with a deficient homologous recombination pathway, the need for proper genomic testing emerged that not only enables the detection of BRCA1 and BRCA2 mutations, but also the evaluation of genomic instability.